AVM0703 selectively ablates T and B lymphocytes and monocytes, and lymphodepletes neutrophils at the target clinical dose. Basophils (reduced only at the 6 hour time point) and eosinophils (reduced only at the 24 and 48 hour time points), platelets, RBCs are spared, and HSC and MSC are spared or increased.
We at AVM believe that there should be a treatment option that allows you to have a good quality of life with your loved ones without exhausting your financials.
The ability to be able to replace toxic chemotherapy represents investing and partnering opportunity that is not only significant in monetary value but also impactful in social value.
In the U.S. alone, total patients who can be treated with AVM0703 represent a $30B dollar annual revenue opportunity.